Previous 10 | Next 10 |
The DISARM Act of 2019 provides the framework needed to stabilize the antimicrobial ecosystem, spur development of new infection-fighting drugs, and preserve the effectiveness of existing medicines for drug-resistant infections WASHINGTON , June 7, 2019 /PRNewswire/ -- The Antimi...
DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 22, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive...
NEW YORK, May 13, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Nabriva Therapeutics plc (“Nabriva” or the “Company”) (NASDAQ:NBRV) of the July 8, 2019 deadline to seek the role of lead plaintiff i...
DUBLIN, Ireland, May 10, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months ended March 31, 2019 ...
DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 08, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive...
DUBLIN, Ireland, May 08, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, announced that the Company’s marketing authorization application ...
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Nabriva Therapeutics plc (“Nabriva” or the “Company”) (NASDAQ: NBRV ) investors concerning the Company and its officers’ possible violations of federal securiti...
BOSTON, May 02, 2019 (GLOBE NEWSWIRE) -- Block & Leviton LLP ( www.blockesq.com ), a national securities litigation firm, is investigating whether Nabriva Therapeutics plc (“Nabriva” or the “Company”) (NASDAQ: NBRV) and certain of its officers and directors...
NEW YORK, NY / ACCESSWIRE / May 2, 2019 / Bronstein, Gewirtz & Grossman, LLC isinvestigating potential claims on behalf of purchasers of Nabriva Therapeutics PLC ("Nabriva" or the "Company") (NASDAQ: NBRV). Such investors are encouraged to obtain additional information and assist the inv...
Gainers: ARCA biopharma (NASDAQ: ABIO ) +37% . MFC Bancorp (NYSE: MFCB ) +32% . Enphase Energy (NASDAQ: ENPH ) +29% . Precipio (NASDAQ: PRPO ) +25% . Nu Skin Enterprises (NYSE: NUS ) +25% . Nanometrics Incorporated (NASDAQ: NANO ) +22% . Qumu Corporation (NASDAQ: QUMU ) +22% ....
News, Short Squeeze, Breakout and More Instantly...
Nabriva Therapeutics plc Company Name:
NBRV Stock Symbol:
NASDAQ Market:
-Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations- -Company To Continue Work With Torreya Capital On Asset Monetization- DUBLIN, Ireland, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV) today announced that, after an assessment ...
- PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects – - Results Support Potential Utility of Lefamulin in Patients with Cystic Fibrosis - DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Na...
- Shifted Focus to SIVEXTRO to Enable Cost Cutting - - Cash Runway Extended into Q1 2023 - - Q3 2022 Total Revenue of $9.2 Million - - Engaged Torreya Capital As Strategic Advisor - - Conference call today at 4:30 p.m. Eastern Time - DUBLIN, Ireland, ...